Bayer launches recruitment drive in Saudi Arabia

By 2021, the company aims to recruit more than 140 additional team members within its pharmaceuticals and consumer health divisions.
Short Url
Updated 07 April 2020

Bayer launches recruitment drive in Saudi Arabia

Bayer, a German multinational pharmaceutical and life sciences company, has launched a focused campaign “Move Forward with Bayer” in Saudi Arabia, designed to drive the recruitment of Saudi nationals within its pharmaceutical business in the region.

The digitally led campaign is designed to appeal to pharmaceutical graduates, with a dedicated micro-site and animated characters, Mouna and Youssef, helping in bringing it to life. By 2021, the company aims to recruit more than 140 additional team members within its pharmaceuticals division for prescription-based medicines and its over-the-counter consumer health division, specifically recruiting for the roles of product specialists and medical sales representatives.

The “Move Forward with Bayer” campaign is aligned with the broader initiatives of the government of Saudi Arabia to nationalize its workforce in key industries, driving the diversification beyond oil and the Saudization of both public and private sector employees.

HIGHLIGHT

The ‘Move Forward with Bayer’ campaign is aligned with the broader initiatives of the government of Saudi Arabia to nationalize its workforce in key industries, driving the diversification beyond oil and the Saudization of both public and private sector employees.

Hussein El-Hakim, managing director — Saudi Arabia at Bayer, said: “Since we first launched operations in Saudi Arabia, our goal has been not only to bring our philosophy and purpose of ‘Science for a Better Life’ to the market, but to identify and nurture Saudi talent in our commitment to the localization of our business activities and the creation of rewarding employment opportunities for nationals.

“Our ‘Move Forward with Bayer’ campaign underlines our support of the goals of Saudi Vision 2030 and we look forward to a successful outcome through effective partnerships that will drive the upskilling of Saudi talent.”

He added: “For many years, Bayer has been committed to achieving gender balance in its workforce and this is very much the case in Saudi Arabia as we continue to expand our operations across our pharmaceuticals division. We look forward to building on our existing, diverse team with new talent and to promoting a culture of inclusion and diversity.”

Reda Zaidan, human resources business partner — Saudi Arabia at Bayer, said: “In line with our global practices, fostering employees’ individual abilities in Saudi Arabia in terms of talents and strengths is key to Bayer’s future growth and success. Sustained success is only possible if we create working conditions that allow all employees to utilize their talents optimally and contribute to innovative solutions, enabling them to truly ‘Move Forward with Bayer.’ We hope this campaign goes some way in attracting Saudi talent in the health care sector and supporting not just Bayer’s corporate vision of ‘health for all, hunger for none,’ but the broader goals of the nation in terms of health care provision and Saudization targets, too.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.